Lesson
HPA Axis, Circadian Timing, and Stress
Adrenal glucocorticoid exposure begins with a pulsatile, circadian control system that changes rapidly during stress and is suppressed by exogenous steroid feedback.
- CRH and vasopressin
- ACTH
- MC2R and MRAP
- Circadian cortisol
- Negative feedback
Hypothalamus drives pituitary ACTH and adrenal cortisol synthesis
Cortisol output rises near waking and during physiologic stress
Endogenous and exogenous glucocorticoids reduce CRH and ACTH
Trace the endocrine signal
Hypothalamic CRH and vasopressin stimulate pituitary corticotrophs to release ACTH. ACTH binds melanocortin 2 receptors in the adrenal cortex, with MRAP required for normal receptor function, and promotes cortisol synthesis and adrenal trophic support.
Link the surface signal to synthesis
MC2R is a G-protein-coupled surface receptor. ACTH activates Gs and cAMP signaling, including protein kinase A, to increase cholesterol availability and StAR-mediated mitochondrial delivery. Longer stimulation also regulates steroidogenic enzyme expression. This differs from cortisol acting through an intracellular glucocorticoid receptor.
Respect time and stress
Cortisol secretion is pulsatile and usually highest near waking and lowest around midnight. Illness, surgery, trauma, hypoglycemia, and other stressors increase demand, so a single cortisol value must be interpreted through time, stress, binding, and exogenous exposure.
Close the feedback loop
Cortisol and synthetic glucocorticoids reduce CRH and ACTH signaling. Sustained feedback can reduce adrenal stimulation and eventually adrenal responsiveness, which is why abrupt withdrawal after sufficient exposure can reveal glucocorticoid deficiency.
Quick check
Checking for saved practice…
Lesson
Adrenal Cortex Zones and Hormone Outputs
The adrenal cortex is chemically organized by zone, with enzyme expression and regulators directing cholesterol toward mineralocorticoids, glucocorticoids, or adrenal androgens.
- Zona glomerulosa
- Zona fasciculata
- Zona reticularis
- Angiotensin II and potassium
- ACTH
Angiotensin II and potassium regulate aldosterone
ACTH supports cortisol synthesis
ACTH contributes to adrenal androgen production
Assign the glomerulosa
The outer zona glomerulosa produces aldosterone. Angiotensin II and potassium are principal regulators, and aldosterone synthase completes the mineralocorticoid pathway. This zone lacks meaningful CYP17A1 activity, which limits cortisol and androgen synthesis.
Assign the fasciculata
The middle zona fasciculata produces cortisol under strong ACTH regulation. Its enzyme pattern supports 17-hydroxylation and 11-beta-hydroxylation but not the final aldosterone-synthase sequence.
Assign the reticularis
The inner zona reticularis produces DHEA, DHEA sulfate, androstenedione, and related adrenal androgens. ACTH contributes to regulation, while enzyme balance favors 17,20-lyase activity and androgen precursors.
Quick check
Checking for saved practice…
Lesson
Cholesterol and Adrenal Steroidogenesis
Every adrenal steroid begins with cholesterol, but mitochondrial transport and zone-specific enzymes determine whether the final product is cortisol, aldosterone, or an androgen precursor.
- StAR
- CYP11A1
- CYP17A1
- CYP21A2
- CYP11B1 and CYP11B2
Mitochondrial cholesterol becomes pregnenolone
Distinct hydroxylase and lyase reactions direct steroid branches
Distinct mitochondrial enzymes complete cortisol or aldosterone
Enter the mitochondrion
StAR moves cholesterol to the inner mitochondrial membrane, where CYP11A1 removes the side chain to form pregnenolone. This is the common entry step for adrenal steroid synthesis and a key point of acute ACTH regulation.
Build the cortisol branch
CYP17A1 converts pregnenolone to 17-hydroxypregnenolone. HSD3B2 then forms 17-hydroxyprogesterone; CYP21A2 converts it to 11-deoxycortisol. Mitochondrial CYP11B1 adds the 11-beta hydroxyl to produce cortisol. A block can reduce downstream hormone while increasing upstream precursors.
Separate aldosterone and androgen branches
In the glomerulosa, CYP21A2 converts progesterone to deoxycorticosterone, then CYP11B2 performs the successive reactions leading to aldosterone. In the reticularis, CYP17A1 also has 17,20-lyase activity: it cleaves 17-hydroxypregnenolone to DHEA. Hydroxylation and side-chain cleavage are distinct reactions of the same enzyme.
Quick check
Checking for saved practice…
Lesson
Glucocorticoid Receptor Signaling
Glucocorticoids change cell behavior by entering cells, binding an intracellular receptor complex, moving to the nucleus, and altering transcription through direct and indirect mechanisms.
- NR3C1
- Heat-shock proteins
- GRE binding
- Transactivation
- Transrepression
Ligand changes a chaperone-associated receptor conformation
Activated receptor reaches chromatin and transcriptional machinery
Direct and indirect signaling changes inflammation and metabolism
Activate the receptor complex
Unbound glucocorticoid enters the cell and binds the glucocorticoid receptor, or NR3C1, within a chaperone-associated cytosolic complex. Ligand binding changes receptor conformation, releases selected chaperones, and promotes nuclear translocation.
Regulate genes directly
Receptor dimers can bind glucocorticoid response elements and recruit transcriptional coregulators. This transactivation contributes to metabolic programs, anti-inflammatory proteins, and many dose-limiting adverse effects.
Allow for rapid effects
Gene regulation explains much of glucocorticoid action, but rapid, non-genomic effects also occur. A transcription-focused diagram is a teaching model, not proof that every response requires new protein synthesis.
Modify inflammatory networks
Ligand-bound receptor can also influence NF-kappa B, AP-1, chromatin, and other transcriptional machinery. These interactions reduce inflammatory mediators, but a simple transactivation-versus-transrepression split does not fully explain clinical efficacy or toxicity.
Quick check
Checking for saved practice…
Lesson
Mineralocorticoid Receptor and 11-Beta-HSD2
Aldosterone achieves tissue selectivity not because cortisol cannot bind the mineralocorticoid receptor, but because selected tissues enzymatically protect that receptor from cortisol.
- NR3C2
- Aldosterone
- Cortisol competition
- 11-beta-HSD2
- Sodium and potassium handling
Both can bind the mineralocorticoid receptor with high affinity
Local cortisol inactivation preserves aldosterone selectivity
MR signaling promotes sodium retention and potassium secretion
Recognize receptor overlap
The mineralocorticoid receptor, or NR3C2, can bind aldosterone and cortisol with high affinity. Circulating cortisol is far more abundant, so receptor selectivity requires local enzymatic control rather than ligand affinity alone.
Protect the receptor
In aldosterone-sensitive epithelia, 11-beta-HSD2 converts active cortisol to cortisone, which has little mineralocorticoid receptor activity. Inhibition or deficiency of this enzyme allows cortisol to drive sodium retention, potassium loss, and hypertension.
Translate signaling into transport
Activated mineralocorticoid receptor increases epithelial sodium transport and supports potassium and hydrogen secretion in the distal nephron. Fludrocortisone exploits this pathway, while glucocorticoids differ markedly in residual mineralocorticoid activity.
Monitor replacement in its disease context
For primary adrenal insufficiency with confirmed aldosterone deficiency, monitor salt craving, postural symptoms, edema, blood pressure and electrolytes during fludrocortisone replacement. The endocrine guideline advises against routine salt restriction in this setting. Hypertension prompts dose reassessment; persistent hypertension may need antihypertensive treatment while necessary replacement continues. Do not automatically transfer this plan to glucocorticoid-induced insufficiency.
Recognize potassium-lowering combinations
Fludrocortisone can amplify potassium loss from loop or thiazide diuretics and amphotericin B. Hypokalemia can increase digoxin-related arrhythmia risk. Check electrolytes and the full medication list when weakness, palpitations or excess fluid retention develops; correct the cause rather than assuming replacement doses cannot cause harm.
Quick check
Checking for saved practice…
Lesson
Corticosteroid Scaffold and Structure-Activity Relationships
Small changes to the four-ring steroid scaffold can markedly shift receptor potency, mineralocorticoid activity, metabolic stability, and duration.
- 3-Keto-4-ene motif
- 11-beta-hydroxyl
- 1,2 double bond
- 9-alpha-fluorine
- 6 and 16 substitutions
The active alcohol supports glucocorticoid receptor recognition
These changes raise glucocorticoid selectivity and reduce salt retention
The complete substitution pattern shapes receptor activity
Keep the active glucocorticoid pattern
The corticosteroid nucleus contains four fused rings. Classical agents share a 3-keto-4-ene A-ring pattern. Oxygenated groups, including the 11-beta hydroxyl, the C17 substituents and the side chain extending to C21, shape receptor recognition; the complete ligand-pocket fit matters. Oxidation of 11-beta-hydroxyl creates a less active 11-keto prodrug in selected pairs.
Increase glucocorticoid selectivity
A 1,2 double bond, as in prednisolone, increases glucocorticoid potency and reduces relative mineralocorticoid activity. A 6-alpha-methyl group, as in methylprednisolone, further reduces salt-retaining activity.
Use fluorine and C16 substitution carefully
A 9-alpha-fluorine strongly increases receptor potency and can increase mineralocorticoid activity. The C16 alpha-methyl of dexamethasone and beta-methyl of betamethasone help reduce mineralocorticoid activity. A C16 hydroxyl is a different modification; triamcinolone remains an intermediate-acting agent. Predict activity from the complete structure rather than assigning every C16 substituent the same potency or duration.
Quick check
Checking for saved practice…
Lesson
The Clinical Glucocorticoid Family
Hydrocortisone, prednisone, prednisolone, methylprednisolone, triamcinolone, dexamethasone, and betamethasone occupy different positions on the potency, duration, and mineralocorticoid spectrum.
- Short acting
- Intermediate acting
- Long acting
- Mineralocorticoid activity
- Fludrocortisone
Endogenous-like exposure with meaningful mineralocorticoid activity
Flexible systemic anti-inflammatory exposure with varied activation
High potency and long action with little mineralocorticoid effect
Use short and intermediate agents deliberately
Hydrocortisone resembles endogenous cortisol and retains meaningful mineralocorticoid activity. Prednisone, prednisolone, methylprednisolone, and triamcinolone provide progressively different activation, potency, and salt-retaining profiles over an intermediate duration.
Reserve long-acting potency for a reason
Dexamethasone and betamethasone are highly potent, long acting, and have minimal mineralocorticoid activity. Their prolonged biologic effect can be useful, but it can also complicate titration, circadian replacement, and HPA recovery.
Separate mineralocorticoid replacement
Fludrocortisone is a strongly mineralocorticoid synthetic steroid with glucocorticoid activity at higher exposure. It is used when sodium-retaining hormone action is needed, not as a routine substitute for every anti-inflammatory glucocorticoid.
Quick check
Checking for saved practice…
Lesson
Activation, Disposition, and Local Delivery
Corticosteroid exposure depends on conversion between active and inactive forms, protein binding, hepatic metabolism, route, tissue esterification, and first-pass extraction.
- Prednisone activation
- Cortisone activation
- CBG and albumin
- CYP3A4
- Local and low-bioavailability delivery
Prednisone and cortisone require conversion to active alcohols
Disposition and interacting drugs alter free and total exposure
Route and first-pass extraction can reduce but not erase systemic effects
Activate 11-keto prodrugs
Prednisone requires conversion to prednisolone, and cortisone requires conversion to cortisol, largely through 11-beta-HSD1. Severe hepatic dysfunction or altered enzyme activity can make prodrug exposure less predictable than direct active-drug dosing.
Account for binding and metabolism
Cortisol binds corticosteroid-binding globulin (CBG) and albumin. Prednisolone also binds CBG, whereas many other synthetic glucocorticoids predominantly bind albumin; budesonide has little or no CBG binding. CYP3A4 contributes to metabolism of several agents, so strong inhibitors can raise systemic exposure and inducers can lower it.
Design delivery to limit exposure
Inhaled, intranasal, topical, intra-articular, and gut-targeted products can concentrate action near the disease site. For inhaled budesonide, hepatic first-pass metabolism limits exposure from the swallowed fraction; drug absorbed through the lungs initially bypasses that first pass. Its active parent is metabolized mainly through CYP3A4 to much less active metabolites. Nonoral treatment can still suppress the HPA axis, especially with high doses, prolonged use, overlapping routes or metabolic inhibition.
Quick check
Checking for saved practice…
Lesson
Corticosteroid Formulation Chemistry
Chemical modification of steroid hydroxyl groups can create water-soluble injectable products, depot preparations, tissue-retained local drugs, and inactive prodrugs that must be converted before receptor binding.
- C21 phosphate and succinate
- Lipophilic esters
- Acetonides
- Prodrug hydrolysis
- Tissue residence
Ionizable promoieties support aqueous parenteral delivery
Poor solubility can slow release; an ester is not always a prodrug
Chemical identity and dosage form jointly shape exposure
Make rapid parenteral delivery possible
Ionizable phosphate or hemisuccinate groups attached to an accessible hydroxyl can markedly increase aqueous solubility. Hydrolysis releases the parent steroid from such prodrugs, but conversion rate and completeness depend on the derivative. Human methylprednisolone studies found faster conversion from phosphate than hemisuccinate; neither a shared parent nor a water-soluble formulation proves identical early exposure. Check the labeled basis of strength: Solu-Medrol expresses sodium succinate content as the equivalent amount of methylprednisolone. Do not apply an extra molecular-weight conversion to that labeled amount. Matching steroid amounts still does not establish interchangeable routes or release profiles.
Verify the injectable product and route
Solu-Medrol sodium succinate is a soluble product labeled for IV or IM administration. Depo-Medrol acetate is a suspension and must not be given IV. Both labels contraindicate intrathecal administration and warn of serious neurologic events with epidural administration, for which corticosteroids are not approved. Product, concentration, diluent, route and prescribed indication must all match.
Check presentation-specific ingredients
The reviewed Solu-Medrol 40 mg presentation contains lactose derived from cow's milk and is contraindicated with known or suspected hypersensitivity to cow's milk or its components. This allergy precaution is not the same as lactose intolerance. Benzyl-alcohol-containing formulations and diluents require separate neonatal/prematurity review; do not assume every vial or diluent has identical excipients.
Create local or depot residence
Poorly soluble depot preparations can release drug slowly, but an ester group does not automatically make a corticosteroid an inactive prodrug. Mometasone furoate itself binds the glucocorticoid receptor; its attached furoate contributes to binding. Distinguish prodrug conversion from an active ester and from slow dissolution of a suspension. Local persistence can coexist with systemic absorption and HPA suppression.
Use cyclic acetals to tune local pharmacology
Triamcinolone acetonide contains a cyclic 16,17 group derived from acetone; budesonide instead contains a 16,17 acetal derived from butyraldehyde. Budesonide is not an acetonide. These modifications are part of the drug structure, not simply counterions or proof that activation by cleavage is required. Budesonide itself is active. Both drugs are poorly water soluble; duration and tissue exposure also depend on the complete dosage form, delivery and metabolism.
Quick check
Checking for saved practice…
Lesson
Mineralocorticoid Receptor Antagonists
Spironolactone and eplerenone interrupt aldosterone signaling at the mineralocorticoid receptor, but their steroid-like structures, selectivity, metabolism, and interaction profiles are not identical.
- Spironolactone
- Active metabolites
- Eplerenone
- Selectivity
- Potassium and kidney function
Spironolactone and eplerenone compete at the mineralocorticoid receptor
Active metabolites, off-target effects, and CYP3A interactions differ between agents
Reduced potassium secretion creates predictable laboratory risk
Preserve the antagonist pharmacophore
Both drugs have a steroidal framework and a lactone ring, but their substituents differ. Spironolactone includes a sulfur-containing C7 group; eplerenone contains a 9,11 epoxide and a C7 ester. Compare the complete structures with their measured receptor and metabolic profiles; a single functional group does not by itself establish clinical selectivity.
Distinguish the two clinical profiles
Spironolactone forms active metabolites and interacts with androgen and progesterone receptors, which helps explain gynecomastia, breast symptoms, and menstrual effects. Eplerenone is more selective for the mineralocorticoid receptor and has no identified active metabolites in human plasma, but CYP3A-mediated clearance creates important inhibitor restrictions.
Protect potassium and renal function
Both agents reduce aldosterone-mediated sodium retention and potassium secretion. Hyperkalemia risk rises with impaired kidney function, higher baseline potassium, renin-angiotensin system blockers, potassium supplements, and other potassium-raising drugs, so laboratory follow-up is part of the mechanism-based prescription.
Apply spironolactone exclusions and follow-up
Aldactone is contraindicated with hyperkalemia, Addison disease or concurrent eplerenone. Check potassium within one week of initiation or titration and regularly afterward; renal impairment or interacting drugs may require earlier or more frequent checks. Review potassium supplements and potassium-containing salt substitutes. Hyperkalemia requires dose reduction or discontinuation and treatment; also monitor volume status and kidney function.
Keep eplerenone eligibility indication-specific
The Inspra label excludes initiation with potassium above 5.5 mEq/L, creatinine clearance at or below 30 mL/min, or strong CYP3A inhibitors. Hypertension adds exclusions: type 2 diabetes with microalbuminuria, creatinine above 2.0 mg/dL in males or 1.8 mg/dL in females, creatinine clearance below 50 mL/min, or potassium supplements/potassium-sparing diuretics. These label boundaries are not a substitute for stricter disease-specific guideline criteria.
Schedule eplerenone monitoring
Measure potassium before treatment, within the first week, one month after initiation or dose adjustment, and periodically thereafter. Check potassium and creatinine within three to seven days after adding a moderate CYP3A inhibitor, ACE inhibitor, ARB or NSAID. With moderate CYP3A inhibitors, the label caps post-MI HFrEF treatment at 25 mg daily; hypertension starts at 25 mg daily and may increase to 25 mg twice daily. Strong inhibitors are contraindicated.
Review more than potassium alone
Spironolactone can reduce lithium clearance and interfere with some digoxin assays. Avoid concurrent mitotane; concurrent abiraterone is not recommended. Its antiandrogenic effects warrant avoidance during pregnancy or counseling about potential fetal risk. Take Aldactone consistently with respect to meals. These considerations require medication-specific review even when potassium is currently normal.
Quick check
Checking for saved practice…
Lesson
Glucocorticoid Dose Equivalence and Conversion
Equivalence tables compare approximate anti-inflammatory exposure, but a safe conversion also accounts for schedule, duration, route, mineralocorticoid activity, and the disease being treated.
- Hydrocortisone 20 mg
- Prednisone 5 mg
- Methylprednisolone 4 mg
- Dexamethasone 0.75 mg
- Daily-dose conversion
Use a common approximate potency anchor
Scale the complete daily dose through equivalent units
Duration, route, mineralocorticoid action, and indication still differ
Use a common reference
A commonly used approximate anti-inflammatory equivalence is hydrocortisone 20 mg, prednisone or prednisolone 5 mg, methylprednisolone 4 mg, and dexamethasone 0.75 mg. Cortisone 25 mg is also often treated as approximately equivalent to hydrocortisone 20 mg.
State the reference and route
Triamcinolone 4 mg is another approximate equivalent to prednisone 5 mg. Betamethasone values vary by reference: RxPrep uses 0.6 mg, while the reviewed Celestone label comparison uses 0.75 mg. State the chosen reference rather than treating these estimates as exact constants. The label limits its equivalence comparison to oral or intravenous exposure; depot intramuscular and joint injections can behave differently. A comparison table does not authorize an unlisted administration route for a particular product.
Convert total daily exposure
Multiply the source total daily dose by the ratio of target-equivalent dose to source-equivalent dose. For example, methylprednisolone 32 mg daily corresponds approximately to prednisone 40 mg daily because each 4 mg of methylprednisolone maps to 5 mg of prednisone.
Read a dose pack as a specific prescription
The standard Medrol 4 mg Dosepak contains 21 tablets over six days: daily totals are 24, 20, 16, 12, 8 and 4 mg. Its label permits all six first-day tablets together or divided later that day unless the prescriber directs otherwise. This packaged course is not a universal regimen for inflammatory disease or long-term steroid withdrawal.
Name the limits
Equivalent anti-inflammatory doses do not create the same biologic duration, peak, mineralocorticoid activity, formulation behavior, or HPA effect. Conversion supports an initial plan, while indication, clinical response, and safety monitoring determine the final regimen.
Quick check
Checking for saved practice…
Lesson
Cumulative Exposure, HPA Suppression, and Withdrawal
Glucocorticoid harm is shaped by total exposure and susceptibility, while HPA recovery varies enough that taper decisions must combine disease control, duration, potency, route, symptoms, and endocrine context.
- Metabolic and cardiovascular toxicity
- Bone, eye, skin, muscle, and growth
- Infection and vaccination
- HPA suppression
- Taper principles
Multiple products and metabolic inhibitors can accumulate
Monitor metabolic, infectious, skeletal, ocular, and endocrine effects
Reduce faster above physiologic exposure and more slowly near recovery
Monitor the whole toxicity pattern
Systemic glucocorticoids can worsen glucose, blood pressure, fluid balance, mood, sleep, infection risk, bone loss, myopathy, skin fragility, cataract, glaucoma, and growth. Risk depends on dose and duration, but susceptible patients can experience important harm early.
Act on bone risk early
For adults starting or continuing prednisone-equivalent doses of at least 2.5 mg/day for more than three months, assess fracture risk promptly. Include fracture/fall history, bone density and vertebral assessment when available; FRAX applies from age 40. Reassess during ongoing treatment, commonly every one to two years. Optimize calcium, vitamin D and lifestyle measures. Adults aged 40 or older at moderate, high or very high risk need osteoporosis medication assessment; supplements alone are insufficient. Choose treatment through risk, kidney function, reproductive plans and patient preferences.
Distinguish vaccine risk from HPA suppression
CDC considers systemic prednisone-equivalent exposure of at least 2 mg/kg/day, or at least 20 mg/day in people above 10 kg, for at least 14 consecutive days a high-dose live-virus-vaccine concern. Defer live-virus vaccination for at least one month after stopping that course. This vaccine threshold is not the endocrine taper threshold.
Avoid blanket vaccine exclusions
Short courses, physiologic replacement, lower doses and inhaled or topical treatment alone usually do not prohibit live-virus vaccines. Assess other immunosuppressants and vaccine-specific contraindications. Non-live vaccines do not pose the same infection risk, although immune response may be reduced. Coordinate vaccination before planned immunosuppression when feasible without delaying necessary disease treatment.
Make infection screening exposure-specific
Before prolonged immunosuppressive Medrol, screen hepatitis B and arrange specialist management when positive. Assess suspected Strongyloides because steroids can precipitate dangerous dissemination. Investigate unexplained diarrhea or relevant tropical exposure for amebiasis. Patients receiving immunosuppressive doses should seek prompt advice after measles or chickenpox exposure. Infection precautions require organism-specific assessment, not a blanket claim that steroids are never used during infection.
Recheck interacting treatment when steroids change
Methylprednisolone can alter oral anticoagulant effects in either direction; monitor coagulation. Chronic high-dose aspirin exposure may rise when methylprednisolone is withdrawn. Cyclosporine coadministration can increase toxicity, including reported convulsions. Review interacting drugs when starting, adjusting or stopping therapy.
Recognize hidden cumulative exposure
Oral, injected, inhaled, intranasal, topical, and ocular products can overlap. Long-acting agents, evening dosing, repeated courses, large local doses, multiple routes, and CYP3A4 inhibitors can increase suppression risk even when no single prescription appears extreme.
Taper for the right reason
Current endocrine guidance generally does not require tapering solely to protect the HPA axis after treatment shorter than three to four weeks. Long-term therapy is tapered only when the underlying disease permits, usually faster at supraphysiologic doses and more slowly near physiologic exposure, with education for stress and crisis symptoms when suppression is possible.
Choose recovery assessment at the right stage
Do not routinely test adrenal recovery while supraphysiologic treatment is still required. Near physiologic dosing, use a supervised gradual taper or morning cortisol assessment. Interpret results with assay and sampling context; do not stop replacement on an isolated, poorly timed result.
Interpret a valid recovery sample
For supervised recovery testing after reaching physiologic dosing, the joint guideline uses an 8-9 AM cortisol after holding glucocorticoid for at least 24 hours; dexamethasone needs a separate plan because of its prolonged effect. Results above 10 micrograms/dL support recovery; 5-10 generally means continue physiologic replacement and repeat in weeks to months; below 5 means continue and reassess later. These are approximate guides affected by sleep, binding proteins and assay. A medication hold requires a clinician's plan and must not delay crisis treatment.
Separate steroid-induced insufficiency from Addison disease
Exogenous glucocorticoid suppression reduces hypothalamic-pituitary drive and is not the same as primary adrenal destruction. The joint endocrine guideline recommends against fludrocortisone for glucocorticoid-induced adrenal insufficiency. Its mineralocorticoid-replacement role in primary adrenal insufficiency must not be generalized to steroid withdrawal.
Plan for illness before the taper ends
Patients with current or recent exposure whose recovery has not been established need an individualized stress-coverage plan. Oral coverage can suit minor stress when stable and absorbing medicine. Hemodynamic instability, prolonged vomiting or diarrhea, or major stress requires parenteral coverage. Suspected adrenal crisis needs urgent parenteral glucocorticoids and fluid resuscitation; do not delay care for recovery testing.
Quick check
Checking for saved practice…
Module practice
Check the connections.
Each attempt draws 10 questions from the complete 42 question bank.
Each attempt draws a fresh set and rearranges the answer choices.
References
Current clinical foundation.
Core source material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.
- GR Ligand Recognition: Structural and Binding Study (2016)
- Human Methylprednisolone Phosphate and Hemisuccinate Comparison (1988 Study Abstract)
- Glucocorticoid Receptor Structures: Cortisol and Mometasone Furoate (2014)
- 2024 Joint Guideline: Full Recovery-Testing Rationale
- Endotext Congenital Adrenal Hyperplasia: Steroidogenesis (2026 Publisher PDF)
- ACR 2022 Glucocorticoid-Induced Osteoporosis Guideline Summary (2023 Update)
- Endotext: Glucocorticoid Mechanisms, Structure and Disposition (2018)
- Budesonide Inhalation Suspension: Chemical Identity and Pharmacokinetics
- Triamcinolone Acetonide Suspension: Chemical Identity and Prolonged Exposure
- Solu-Medrol Label: Strength, Routes and Formulation Precautions
- Depo-Medrol Label: Suspension and Route Restrictions
- US Aldactone Prescribing Information
- US Inspra Prescribing Information
- Endotext ACTH Action on the Adrenals: Publisher PDF
- Celestone Soluspan Label: Dose Comparison and Route Limits
- CDC Altered Immunocompetence: Corticosteroids
- NCBI Endotext ACTH action on the adrenals
- Endotext Congenital Adrenal Hyperplasia
- NCBI Endotext adrenal cortex physiology
- 2024 Endocrine Society glucocorticoid-induced adrenal insufficiency guideline
- Endocrine Society primary adrenal insufficiency guideline
- Current dexamethasone prescribing information
- Current Medrol prescribing information
- Current prednisone prescribing information
- Current fludrocortisone prescribing information